Stephanie Viguers

Somerdale

Managing Editor at Healio

Featured in: Favicon

healio.com

Articles

TEMPO trials: Fixed, flexible doses of tavapadon improve motor function in Parkinson’s

2 weeks ago | healio.com | Stephanie Viguers |Shenaz Bagha

Key takeaways: In TEMPO-1, fixed 5 mg and 15 mg doses of tavapadon improved outcomes in patients with Parkinson’s disease. TEMPO-2 showed that a flexible dose was also associated with significant improvements. SAN DIEGO — Fixed and flexible doses of tavapadon significantly improved motor function compared with placebo in patients with Parkinson’s disease, according to a pair of phase 3 trials presented at the American Academy of Neurology annual meeting.
Pridopidine beneficial in subset of patients with Huntington’s

2 weeks ago | healio.com | Stephanie Viguers |Shenaz Bagha

Key takeaways: Pridopidine showed promise in patients with Huntington’s disease who were not on antidopaminergic medications. The safety and tolerability of pridopidine was comparable to placebo. SAN DIEGO — Pridopidine had a positive effect on clinical progression, cognition and motor function in patients with Huntington’s disease who were not on antidopaminergic medications, according to a pre-specified analysis of the PROOF-HD trial.
Felix NeuroAI wristband improves essential tremor outcomes

2 weeks ago | healio.com | Stephanie Viguers

Key takeaways: An AI-powered wristband was more effective than a sham device in improving essential tremor. It could be used as an alternative for patients who have an inadequate response or cannot tolerate oral drugs. SAN DIEGO — A peripheral nerve stimulator powered by AI and worn as a wristband improved essential tremor symptoms and patients’ ability to perform daily activities compared with a sham device, data from the TRANQUIL trial show.
ACCORD-2: AXS-05 delays relapse time to Alzheimer’s disease agitation

2 weeks ago | healio.com | Stephanie Viguers

Key takeaways: There were no new safety signals, and treatment-emergent adverse events were comparable in the AXS-05 group and placebo group. The manufacturer is expected to apply for FDA approval in the coming months. SAN DIEGO — AXS-05 was well-tolerated and significantly delayed the time to agitation relapse compared with placebo in patients with Alzheimer’s disease, according to phase 3 data from the ACCORD-2 trial.
Nightmares may increase risk for early death

2 weeks ago | healio.com | Stephanie Viguers

Key takeaways: Adults who often had distressing dreams had faster biological aging and were more likely to die prematurely. The associations were independent of medication use, including antipsychotics and antidepressants. SAN DIEGO — Frequent distressing dreams may accelerate biological aging and increase the risk for early death, defined by WHO as younger than 70 years, according to a speaker at the American Academy of Neurology Annual Meeting.
Merit E. Cudkowicz, MD, MSc, receives lifetime award for ALS research: ‘I'm not done yet’

2 weeks ago | healio.com | Merit E. Cudkowicz |Stephanie Viguers

SAN DIEGO — At the AAN Annual Meeting, Merit E. Cudkowicz, MD, MSc, FAAN, was honored with the academy’s Lifetime Achievement Award for her extensive work in ALS research. “I have really been blessed with a great career,” Cudkowicz, executive director of the Mass General Brigham Neuroscience Institute and Julieanne Dorn Professor of Neurology at Harvard Medical School, told Healio.
Gene therapy improves motor function in spinal muscular atrophy at 52 weeks

3 weeks ago | healio.com | Bob Herpen |Stephanie Viguers

Key takeaways: Patients treated with onasemnogene abeparvovec recorded higher scores on all metrics vs. sham at 52 weeks. Onasemnogene abeparvovec demonstrated a favorable safety profile. Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 weeks compared with sham in patients aged 2 to 18 years with spinal muscular atrophy, data show.
‘Coming to the clinic soon’: Top AAD takeaways from Joel M. Gelfand, MD, MSCE

1 month ago | healio.com | Joel M. Gelfand |Stephanie Viguers |Kristen Dowd

ORLANDO — The American Academy of Dermatology annual meeting was packed with “massive advancements” across the field, Joel M. Gelfand, MD, MSCE, chief medical editor of Healio Dermatology, said. In this video, Gelfand draws attention to three presentations that he said particularly stood out.
New AAD President Susan C. Taylor, MD, will focus on ‘taking care of dermatologists’

1 month ago | healio.com | Stephanie Viguers |Kristen Dowd

Key takeaways: Susan C. Taylor, MD, FAAD, assumed her role as president at the AAD annual meeting. She said her mission is to help dermatologists give patients the care they need. ORLANDO — Outgoing American Academy of Dermatology President Seemal R. Desai, MD, FAAD, passed the torch to Susan C.
Ivarmacitinib ‘potential new option’ for adults with severe alopecia areata

1 month ago | healio.com | Stephanie Viguers |Kristen Dowd

Key takeaways: A phase 3 study compared two doses of ivarmacitinib with placebo in 330 adults. At week 24, about 35% in the 4 mg group and 40% in the 8 mg group had a SALT score of 20 or less vs. 9% in the placebo group. ORLANDO — Oral ivarmacitinib, administered 4 mg or 8 mg once daily, significantly induced hair regrowth at 24 weeks vs. placebo in adults with severe alopecia areata, according to phase 3 data presented here.